Share Capital (Tables)

6 Months Ended

Jun. 30, 2020

Equity [Abstract]

Summary of Stock Option Activity

A summary of the Company’s option activity related to options to employees and directors, and related information is as followed:

	As of June 30, 2020
	Number of stock options			Weighted average exercise price
Outstanding at beginning of period		371,360		$	9.19
Granted		166,666			9.64
Exercise		(965	)		-
Forfeited		-			-
Cancelled		-			-
Outstanding at end of period		537,061		$	9.35
Vested at end of period		303,509		$	8.87

	For the Year ended December 31, 2019
	Number of stock options			Weighted average exercise price
Outstanding at beginning of period..		398,308		$	11.50
Granted		48,893			6.20
Forfeited		(28,690	)		-
Cancelled		(47,151	)		-
Outstanding at end of period		371,360		$	9.19
Vested at end of period		270,827		$	8.48

Schedule of Stock Options Outstanding

The stock options outstanding as of June 30, 2020 and December 31, 2019, summarized by exercise prices, are as follows:

Exercise price $	Stock options outstanding as of June 30, 2020		Stock options outstanding as of December 31, 2019		Weighted average remaining contractual life – years as of June 30, 2020		Weighted average remaining contractual life – years as of December 31, 2019		Stock options exercisable as of June 30, 2020		Stock options exercisable as of December 31, 2019
4.20		77,846		77,846		5.5		6.0		77,846		77,846
15.75		133,546		133,546		7.3		7.8		105,911		90,641
8.60		11,630		11,630		9.4		9.9		7,265		5,515
9.00		10,000		10,000		8.3		8.8		6,250		4,750
9.64		166,666		-		0.0		-		-		-
5.95		17,503		17,503		9.2		9.7		5688		-
5.06		19,760		19,760		9.3		9.8		4940		-
15.30		38,533		38,533		7.5		8.0		34,032		29,533
(*)		61,577		62,542		6.3		6.8		61,577		62,542
		537,061		371,360		7.8		8.3		303,509		270,827

(*) Less than $0.01.

Schedule of Stock Options Valuation Assumptions

The grant date fair values of stock options granted in the years ended June 30, 2020 and 2019 were estimated using the Black-Scholes valuation model with the following:

	As of June 30, 2020			Year ended December 31, 2019
Expected volatility		135.60	%		132.63%-144.4	%
Risk-free interest		1.20	%		1.49%-2.62	%
Dividend yield		0	%		0	%
Expected life of up to (years)		6			5.282

Schedule of Warrants Outstanding

The remaining outstanding warrants and terms as of June 30, 2020 and December 31, 2019 are as follows:

Issuance date	Outstanding as of June 30, 2020		Outstanding as of December 31, 2019		Exercise Price		Exercisable as of June 30, 2020		Exercisable Through
Series A (2013) (*)		183		183	$	2,754.00		183	April 9, 2023
Series A (2015) (*)		-		683	$	1,377.00		-	April 30, 2020
Series B (2016) (a)(*)		2,770		2,770	$	40.50		2,770	March 14, 2022
Warrant to underwriters 1.2019 (**)		22,767		22,767	$	8.13		22,767	July 14, 2022
Warrant to underwriters 1.2019 (**)		29,500		29,500	$	12.50		29,500	July 15, 2022
Warrant to underwriters 1.2019 (**)		-		12,500	$	12.50		-	January 15, 2020
Warrant to underwriters 12.2019 (**)		45,643		45,643	$	13.13		-	June 27, 2023
Warrant to underwriters 12.2019 (**)		47,619		47,619	$	13.13		-	June 30, 2023
Warrant to underwriters 12.2019 (**)		45,045		45,045	$	13.88		-	June 25, 2023

(*) Prior to January 1, 2019, warrants with non-standard anti-dilution provisions (referred to as down round protection) were classified as liabilities and re-measured each reporting period. On January 1, 2019, the Company adopted the provisions of ASU 2017-11, which indicates that a down round feature no longer precludes equity classification when assessing whether an investment is indexed to an entity’s own stock. The Company used a full retrospective approach to adoption and restated its financial statements as of the earliest period presented. The cumulative effect of adoption of ASU 2017-11 resulted in an adjustment to accumulated deficit as of January 1, 2018 of $20 with a corresponding adjustment to additional paid-in capital.